hero-image-mobile

Let's Build Better Cells Together

MaxCyte® empowers scientists across cell therapy, protein production, and cell-based assay development to move further, faster—backed by 25+ years of experience and a partnership-first approach. Our Flow Electroporation® technology and SeQure DXTM services enable efficient, scalable, and precise engineering of even the most complex cell types. We support your journey from discovery to commercialization—because better partnerships build better cells.

Research Applications

Cell Therapy

Discover scalable engineering to enable safe and potent cell therapies.

Cell Based Assays

Produce assay-ready cells faster with scalable electroporation.

Antibody & Protein Production

Accelerate biotherapeutic development with transient expression for gram-scale protein production.

Viral Vector Production

Transfect adherent or suspension cells to produce a variety of viral vectors.

Gene Editing

Navigate the complexities of genome engineering with highly efficient delivery.

Vaccine Development

Innovate vaccine research with our adaptable platform for production of recombinant proteins, virus-like particles and more.

Our customers are priority number one for MaxCyte

hp-quote-icon

The equipment is reliable, and the customer service is the best I've ever experienced in a biotech company.

Joshua Sasine, Assistant Professor of Medicine at Cedars-Sinai Medical Center

hp-quote-icon

User friendly interface, well established protocols, and (a) supportive MaxCyte team.

Akitsu Hotta, Associate Professor at the Center for iPS Cell Research and Application, Kyoto University

hp-quote-icon

We use (the) MaxCyte ATx for T-cell gene editing. It enables us to achieve high knockdown efficiency. Easy, convenient and reproducible.

Menggui Huang, Principal Scientist

hp-quote-icon

We discussed the optimization of electroporation conditions with MaxCyte researchers, who provided us with more than 15 optimization programs, and finally found the best one for the manufacture of genetically modified T cells. This experience helped us a lot in the development of our T-cell product, and we were very impressed with the kind and reliable discussions with the MaxCyte team.

Shigeki Yagyu, Professor at Shinshu University

hp-quote-icon

Without MaxCyte, we would not have been able to scale our process to the level needed for our clinical program. Compared to other platforms evaluated, with MaxCyte's large-scale, closed-system electroporation process, we are able to drive down COGS, derisk the process, and have a reliable unit operation for gene editing.

Director at a United States biotech

hp-quote-icon

With the continued support from research specialists that is included with purchase of the machine, we are confident in our ability to optimize our transfections. No other company offered this kind of support. The importance of this service cannot be understated as there is continual turnover in the lab.

Graduate student at a United States university

hp-quote-icon

For our lab, we are new to the technology, and so we wanted to partner with a company that offered great products and great customer service. They are willing to go the extra mile to help their customers with any questions or problems they may be having. They are generous with their time and patiently go through the training process with our team.

Joe Huey, Development Technologist I

hp-quote-icon

Expertise. Expertise combined with a scalable device. Expertise in the field.

Postdoctoral student at a United States university

hp-quote-icon

The technical representatives are knowledgeable and very eager to help and develop solutions in any endeavor. Also, they are very proactive with sharing new developments.

Scientist at a global biomedical company

hp-quote-icon

My company had chosen MaxCyte to meet both its research and GMP-scale electroporation needs.

Scientist at CRISPR Therapeutics

Explore the research we've supported

See how MaxCyte technology is advancing our partners' biomedical innovations

CET-app-note@2x
Application Note
Triple-Engineered NYCE cells as T Cell Therapy for Refractory Cancers
DNA-Nanovector@2x
Poster
Clinical Scale Delivery of nS/MARt Vectors for CAR T Cell Engineering
MAR-app-note@2x
Application Note
Highly Efficient CAR T Cell Engineering, with CRISPR and Single-Stranded Cas9 Target Sequences.

We're here throughout your journey

We support cell and gene therapy developers through every stage of the journey—from Discovery and Process Development to Clinical and Commercial Manufacturing. With proven scalable technology, regulatory support, and expert guidance, we help minimize risk and accelerate timelines. Our collaborative approach has supported over 70 clinical trials across diverse indications and is supporting the first every non-viral therapy approved globally.

Maxcyte

Resources

MaxCyte_Icons_-scientific-brief
Scientific Briefs
MaxCyte_Icons_-webinars
Webinars
MaxCyte_Icons_-poster
Scientific Posters
MaxCyte_Icons_-app-note
App Notes
MaxCyte_Icons_-primary-literature
Literature

MaxCyte News

MaxCyte Minute Newsletter: From advances in cell therapy to changes at MaxCyte®, the past few months have been busy. This issue of our newsletter has a lot in store! Let’s dive in.

FEATURED NEWS

March 31, 2025

Latest News